Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy
Authors
Keywords
-
Journal
JOURNAL OF APPLIED GENETICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-07
DOI
10.1007/s13353-023-00796-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
- (2021) Revati Sharma et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
- (2021) Yukun Wang et al. Frontiers in Cell and Developmental Biology
- Author Correction: mTOR at the nexus of nutrition, growth, ageing and disease
- (2020) Grace Y. Liu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models
- (2019) Qianwen Zhang et al. CLINICAL CANCER RESEARCH
- Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model
- (2018) Shani Avniel-Polak et al. ENDOCRINE-RELATED CANCER
- The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2
- (2018) Angel Chao et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
- (2016) Asona Lui et al. BMC CANCER
- Systemic therapy in metastatic renal cell carcinoma
- (2016) Jens Bedke et al. WORLD JOURNAL OF UROLOGY
- In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
- (2015) Sara A. Hurvitz et al. BREAST CANCER RESEARCH AND TREATMENT
- Cellular and molecular effects of the mTOR inhibitor everolimus
- (2015) U. Saran et al. CLINICAL SCIENCE
- Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors
- (2015) Rony A. François et al. JNCI-Journal of the National Cancer Institute
- Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors
- (2015) Rony A. François et al. JNCI-Journal of the National Cancer Institute
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Novel loci associated with usual sleep duration: the CHARGE Consortium Genome-Wide Association Study
- (2014) D J Gottlieb et al. MOLECULAR PSYCHIATRY
- The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy
- (2012) ANAÏS ALTMEYER et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Current and future systemic treatments for renal cell carcinoma
- (2012) Rosalie Fisher et al. SEMINARS IN CANCER BIOLOGY
- Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma
- (2010) Jose A. Karam et al. EUROPEAN UROLOGY
- Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs
- (2010) Jia-Jia Huang et al. INVESTIGATIONAL NEW DRUGS
- Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001
- (2010) Steffen Wedel et al. LIFE SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now